Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 18Recruiting 16Terminated 2Suspended 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1HTLV-I Infections 1

Interventions

Specimen Handling 29Magnetic Resonance Spectroscopy 20Biopsy 19Cyclophosphamide 8venetoclax 5Bevacizumab 5Vincristine 4Taxes 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Etoposide 4Cetuximab 4Azacitidine 4fludarabine phosphate 3fludarabine 3decitabine and cedazuridine drug combination 3X-Rays 3Radiosurgery 3Radiation 3Prednisone 3Doxorubicin 3zanubrutinib 2trastuzumab deruxtecan 2prednylidene 2olaparib 2iadademstat 2deltacortene 2Tacrolimus 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × deltacortene × 90 days × Clear all
NCT04850495 2026-06-04

Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Suspended
38 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04301076 2026-05-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡